TRPM3

FIRST-IN-CLASS TRPM3 ANTAGONIST FOR MIGRAINE AND PAIN

BHV-2100 is Biohaven’s first-in-class molecule directed against TRPM3, a novel druggable calcium channel in the transient receptor potential (TRP) channel family.

BHV-2100 is a highly selective, potent, and peripherally-restricted TRPM3 antagonist that reverses pain in multiple preclinical models, with reduced potential for adverse thermoregulatory side effects, sedation and abuse liability. Inhibition of TRPM3 may provide a novel, non-opioid approach for the treatment of migraine and pain.